Evidence map›Paper›PMID 42807383›Full record

ArticleFrontiers in pediatrics2026

Genetically confirmed severe hemophilia A in a preterm infant: a case report.

Lanjun Mu, Chan Wang, Yuqian Wang, Jing Zhu, Li Zhang, Ning Zou

Abstract readCase Reports
In one paragraph

Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lanjun Mu *Department of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Chan Wang *Department of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Yuqian WangDepartment of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Jing ZhuDepartment of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Li ZhangDepartment of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Ning ZouDepartment of Pediatrics, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe hemophilia A is exceptionally rare among preterm infants. Qwing to immature coagulation system and nonspecific bleeding manifestations, the condition is readily misdiagnosed as other neonatal hemorrhagic disorders, such as vitamin K deficiency, neonatal sepsis and thrombocytopenia. Delayed diagnosis will greatly increase the risk of severe complications, particularly intracranial hemorrhage. Herein, we report a case of genetically confirmed severe hemophilia A in a 34-week preterm infant without family history of hemophilia. Treatment comprised sequential adminnistration of coagulation factor VIII repalcement and emicizumab. We futher analyze the clinical characteristics, diagnostic difficulties and standardized management principles of hemophilia A in preterm infants, so as to improve clinicians' awareness, reduce misdiagnosis and missed diagnosis, and optimize the long-term prognosis of affected infants.

Indexed as

coagulation factor VIIIemicizumabneonatal hemorrhagepreterm infantsevere hemophilia A

Identifiers

PMID42807383
PMCPMC13617031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.